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The life-saving advances over the 60-year history of he-
matopoietic cell transplantation (HCT) have been truly
astounding. The Worldwide Network for Blood and Marrow
Transplantation (WBMT) is committed to making safe and ef-
fective HCT available to all in the global population who could
benefit from it [1]. In resource-limited areas of the world, we
need to emphasize how focused, thoughtful care models can
treat thosewith standard HCT indications and savemany lives.
However, with the new genomics, engineered cellular prod-
ucts, anti-infectives, and remarkable progress in targeted
therapies [2], patients come to transplantation with a lower
disease burden, a better understanding of their disease phe-
notype, and an expectation of better outcomes. Additional
characterization of patient risks based on comorbidities, frailty,
and tailored approaches to necessary supportive care have
allowed expansion of HCT to an older and sicker popula-
tion. This also extends the potential of transplantation therapy
to help many more patients, particularly those in the age
group in which transplantation-targetable diseases are most
prevalent.
All of these advances come with added clinical complexi-
ties and added costs, however. The high price tags of themany
new pharmaceuticals, small molecules, and biologicals are
daunting, but the prices charged and reimbursement paid
should properly be addressed in health policy debates. The
financial burden is also growing due to newly developed di-
agnostic testing, including molecular measures of residual
disease, and newly recognized microbiological and virologi-
cal pathogens. In addition, costly supportive care therapies,
such as those for veno-occlusive disease, thrombotic
microangiopathies, and other life-threatening toxicities, are
contributing to this burden. These can all markedly esca-
late the financial burden facing patients, transplantation
centers, and payers when delivering the life-saving promise
of HCT.
LEARNING TO DO MOREWITH LESS
Can we, as a field, learn to define best practices for safe
and cost-efficient care? Canwe, in the spirit of choosingwisely
[3], define minimal required standards for laboratory moni-
toring, transfusion support, disease burden assessment, and
follow-up care? In addition, for newly developing pro-
grams, particularly in resource-limited regions of the world,
establishing safe and well-planned core elements of HCT
support can allow many patients to benefit from the cura-
tive potential of HCT within affordable limits. We have to ask
whether we will continue to adopt new complex and quite
costly diagnostics and therapeutics, which are intellectual-
ly satisfying but may add only minimal safety or clinical value
to our patients?
To begin this discussion, WBMT led a joint international
session at the BMT Tandem Meetings in February 2017
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addressing the economic issues surrounding HCT, particu-
larly in the developing world, which prompted considerable
discussion (Do Stem Cell Transplants Need to be So
Expensive?).
The complexity of these difficulties cannot be underap-
preciated or underestimated. The scientific, ethical, and
economic challenges in delivering this intensive life-
threatening treatment with wisdom, compassion, and cost-
attentiveness is a stretch goal. Yet we also recognize thatmany
patients who could benefit from HCT do not yet have access,
in both the developed and developing parts of the world.
Learning how to deliver transplantation care must include
teaching ourselves and our successors to do it thoughtfully
and cost-efficiently and will require new skills, new tools, and
refocused attention.
Of course, these problems are of greater importance in
those countries without the necessary economic resources
to increase the number of patients who need this life-
saving procedure, yet the lessons learned may be applied
everywhere. Some published studies from Mexico and India
describe strategies for performing HCT in developing coun-
tries, such as controlling daily hospital bed charges and
physician fees, using more affordable generic drugs when-
ever possible, transitioning procedures to outpatient settings,
avoiding cryopreservation of grafted cells, using reduced-
intensity conditioning, using peripheral blood as a stem cell
source, limiting transfusions, and avoiding expensive and re-
petitive diagnostic studies [4-9]. More information is needed
on describing and testing proposed cost-efficient models that
maximize financial resources without compromising patient
safety. Such research will require collaboration among HCT
centers across the developed and developing world.
Transplantation therapy can save many lives, but it must
be delivered more broadly, and with truncated costs, to a
larger population. If we do not address this expanding fi-
nancial burden, then the necessary societal will, resources,
and dollars will never be available to treat the many pa-
tients who we currently cannot serve. As a field, we should
be proud and excited by the scope of improvements in the
care that we deliver, but we have largely overlooked the dismal
science of health economics. We should judge and measure
the utility and value of each component of care delivered. This
represents a new area for disciplined investigation and a new
opportunity for improvement—both are within the scope of
science and compassionate care delivery. Comparedwith other
therapies for these diseases, HCT generally has been shown
to be a cost-effective therapeutic modality. Nevertheless, we
need to continue to keep moving on the science, while also
learning how to deliver better and more cost-efficient trans-
plantation care.
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